Table 4.
Year 1 no AZT | Isolates pre-AZT | Erythromycin
|
Clarithromycin
|
Azithromycin
|
||||||
---|---|---|---|---|---|---|---|---|---|---|
Sen | Int | Res | Sen | Int | Res | Sen | Int | Res | ||
H. influenzae | 10 (31.3%) | 0 | 0 | 10 | 7 | 2 | 1 | 10 | 0 | 0 |
S. pneumoniae | 6 (18.8%) | 3 | 0 | 3 | 3 | 0 | 3 | 3 | 0 | 3 |
M. catarrhalis | 15 (50%) | 14 | 1 | 1 | 15 | 0 | 1 | 15 | 0 | 0 |
Year 2 AZT therapy | Isolates post AZT | |||||||||
H. influenzae | 1 (20%) | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
S. pneumoniae | 4 (80%) | 0 | 0 | 4 | 0 | 0 | 4 | 0 | 0 | 4 |
M. catarrhalis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Abbreviations: AZT, azithromycin; H. influenzae, Haemophilus influenzae; S. pneumoniae, Streptococcus pneumoniae; M. catarrhalis, Moraxella catarrhalis; SEN, sensitive; INT, intermediate; RES, resistant.